Swift Prime(迅捷 Prime)到底是什麼？
Swift Prime 迅捷 Prime - Methods- We analyzed patients treated with the Solitaire stent retriever in the combined SWIFT (Solitaire FR With the Intention for Thrombectomy), STAR (Solitaire FR Thrombectomy for Acute Revascularization), and SWIFT PRIME (Solitaire FR With the Intention for Thrombectomy as Primary Endovascular Treatment) cohorts. [1] From 2014 to 2015, the five pivotal stroke trials (MR CLEAN, ESCAPE, EXTEND-IA, SWIFT PRIME and REVASCAT) have shown that stroke thrombectomy clearly improved functional outcome of patients with occlusion of the internal carotid artery or the M1 portion of the middle cerebral artery, with a baseline National Institutes of Health Stroke Scale score of ≥6, with a baseline Alberta Stroke Program Early Computed Tomography Score of ≥6, and who could receive thrombectomy within a 6-hour window of symptom onset. [2] Results Ten clinical trials fit the inclusion criteria, including PISTE, REVASCAT, DAWN, THRACE, SWIFT PRIME, ESCAPE, DEFUSE 3, THERAPY, EXTEND-IA, and MR CLEAN, with 2233 patients assessed for mortality alone and 2229 for mortality or severe disability. [3] We applied this approach to the study population from four recent positive acute stroke clinical trials: MR CLEAN, EXTEND-IA, ESCAPE, and SWIFT PRIME, applying published trial criteria to an independent registry of 612 acute stroke patients, since we did not have access to the complete trial data. [4] In contrast, advanced imaging modalities, including CT perfusion and diffusion/perfusion MR imaging, were used to evaluate infarct core and ischemic penumbra in EXTEND-IA, SWIFT PRIME, DAWN and DEFUSE 3 trials. [5] Trial registration numbers SWIFT-NCT01054560; post results, SWIFT PRIME-NCT01657461; post results, STAR-NCT01327989; post results. [6]方) 隊列。 [1] 從 2014 年到 2015 年，五項關鍵卒中試驗（MR CLEAN、ESCAPE、EXTEND-IA、SWIFT PRIME 和 REVASCAT）表明，卒中血栓切除術明顯改善了頸內動脈或中段 M1 部分閉塞患者的功能預後腦動脈，基線美國國立衛生研究院卒中量表評分≥6，基線阿爾伯塔卒中計劃早期計算機斷層掃描評分≥6，並且可以在症狀出現 6 小時內接受血栓切除術。 [2] 結果 10 項臨床試驗符合納入標準，包括 PISTE、REVASCAT、DAWN、THRACE、SWIFT PRIME、ESCAPE、DEFUSE 3、THERAPY、EXTEND-IA 和 MR CLEAN，其中 2233 名患者單獨評估死亡率，2229 名患者評估死亡率或嚴重殘疾. [3] 我們將這種方法應用於最近四項陽性急性卒中臨床試驗的研究人群：MR CLEAN、EXTEND-IA、ESCAPE 和 SWIFT PRIME，將已發表的試驗標準應用於 612 名急性卒中患者的獨立登記處，因為我們無法訪問到完整的試驗數據。 [4] 相比之下，在 EXTEND-IA、SWIFT PRIME、DAWN 和 DEFUSE 3 試驗中，先進的成像方式，包括 CT 灌注和彌散/灌注 MR 成像，被用於評估梗死核心和缺血半暗帶。 [5] 試用註冊號 SWIFT-NCT01054560；發布結果，SWIFT PRIME-NCT01657461；發布結果，STAR-NCT01327989；發布結果。 [6]
U Swift Prime U 斯威夫特總理
Levy: 1; C; Medtronic US SWIFT PRIME Trials. [1] Levy: 1; C; Medtronic US SWIFT PRIME Trials. [2]徵費：1； C;美敦力美國 SWIFT PRIME 試驗。 [1] 徵費：1； C;美敦力美國 SWIFT PRIME 試驗。 [2]
swift prime trial 迅捷 Prime 試用
Levy: 1; C; Medtronic US SWIFT PRIME Trials. [1] Methods- NINDS rt-PA Study (National Institute for Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator) and SWIFT PRIME trial (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment) patients were matched for prognosis (based on age and National Institutes of Health Stroke Scale) and definite/likely anterior circulation large vessel occlusion (based on National Institutes of Health Stroke Scale total score and item pattern), using optimal inverse variance matching, to determine comparative outcomes with nonreperfusion care alone, IVT alone, and IVT+EVT. [2] Levy: 1; C; Medtronic US SWIFT PRIME Trials. [3]徵費：1； C;美敦力美國 SWIFT PRIME 試驗。 [1] 方法 - NINDS rt-PA 研究（國家神經疾病和中風重組組織纖溶酶原激活劑研究所）和 SWIFT PRIME 試驗（以血栓切除術作為主要血管內治療的紙牌）患者的預後匹配（基於年齡和美國國立衛生研究院）卒中量表）和明確/可能的前循環大血管閉塞（基於美國國立衛生研究院卒中量表總分和項目模式），使用最佳逆方差匹配，以確定單獨無再灌注治療、單獨 IVT 和 IVT+EVT 的比較結果. [2] 徵費：1； C;美敦力美國 SWIFT PRIME 試驗。 [3]